WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H561583
CAS#: 85801-02-1
Description: Infree is a prodrug of indomethacin. It acts as a nonsteroidal anti-inflammatory drug (NSAID) and disease-modifying anti-rheumatic drug (DMARD).
Hodoodo Cat#: H561583
Name: Infree
CAS#: 85801-02-1
Chemical Formula: C34H40ClNO4
Exact Mass: 561.26
Molecular Weight: 562.140
Elemental Analysis: C, 72.65; H, 7.17; Cl, 6.31; N, 2.49; O, 11.38
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Infree; INF; Indomethacin farnesil; Indometacin farnesil;
IUPAC/Chemical Name: 3,7,11-Trimethyldodeca-2,6,10-trien-1-yl 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate
InChi Key: CFIGYZZVJNJVDQ-LMJOQDENSA-N
InChi Code: InChI=1S/C34H40ClNO4/c1-23(2)9-7-10-24(3)11-8-12-25(4)19-20-40-33(37)22-30-26(5)36(32-18-17-29(39-6)21-31(30)32)34(38)27-13-15-28(35)16-14-27/h9,11,13-19,21H,7-8,10,12,20,22H2,1-6H3/b24-11+,25-19+
SMILES Code: O=C(OC/C=C(C)/CC/C=C(C)/CC/C=C(C)/C)CC1=C(C)N(C(C2=CC=C(Cl)C=C2)=O)C3=C1C=C(OC)C=C3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 562.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Ono K, Hashimoto T, Satoh T. Eosinophilic pustular folliculitis clinically presenting as orofacial granuloma: successful treatment with indomethacin, but not ibuprofen. Acta Derm Venereol. 2015 Mar;95(3):361-2. doi: 10.2340/00015555-1926. PubMed PMID: 24979363.
2: Hakozaki M, Kikuchi S, Otani K, Tajino T, Konno S. Pseudogout of the acromioclavicular joint: report of two cases and review of the literature. Mod Rheumatol. 2011 Aug;21(4):440-3. doi: 10.1007/s10165-011-0417-8. Epub 2011 Feb 5. Review. PubMed PMID: 21298395.
3: Satoh K, Takano S, Kobayashi T. Keishikajutsubuto (Guizhi-shu-fu-tang) treatment for refractory accumulation of synovial fluid in a patient with pustulotic arthro-osteitis. Fukushima J Med Sci. 2007 Jun;53(1):33-8. PubMed PMID: 17957964.
4: Fujita Y, Fujii T, Takeda N, Tanaka M, Mimori T. Successful treatment of primary Sjögren's syndrome with chronic natural killer lymphocytosis by high-dose prednisolone and indomethacin farnesil. Intern Med. 2007;46(5):251-4. Epub 2007 Mar 1. PubMed PMID: 17329922.
5: Hirohata S, Yanagida T, Kawai M, Kikuchi H. Inhibition of human B cell activation by a novel nonsteroidal anti-inflammatory drug, indometacin famesil. Immunopharmacology. 1999 Nov;44(3):245-54. PubMed PMID: 10598881.
6: Sekine K, Nakajima Y, Sawamoto S, Yamada K, Nakajima M, Miyasaka T, Arioka H, Nakano J, Yamashita N, Ohta K, Mano K. [Vasculo-Behcet's disease with fatal massive hemoptysis]. Nihon Kokyuki Gakkai Zasshi. 1999 Feb;37(2):135-9. Japanese. PubMed PMID: 10214043.
7: Takayama F, Miyazaki T, Aoyama I, Tsukushi S, Sato M, Yamazaki C, Shimokata K, Niwa T. Involvement of interleukin-8 in dialysis-related arthritis. Kidney Int. 1998 Apr;53(4):1007-13. PubMed PMID: 9551411.
8: Hirohata S, Konuma K, Inoue T, Ito K. Interaction of indometacin farnesil, a new nonsteroidal antiinflammatory drug with peripheral blood mononuclear cells from patients with rheumatoid arthritis. Nihon Rinsho Meneki Gakkai Kaishi. 1996 Apr;19(2):136-44. PubMed PMID: 8705690.
9: Nomura K, Sasaki C, Murai T, Mitsuhashi Y, Sato S. Angiolymphoid hyperplasia with eosinophilia: successful treatment with indomethacin farnesil. Br J Dermatol. 1996 Jan;134(1):189-90. PubMed PMID: 8745919.
10: Arakawa T, Fukuda T, Nakagawa K, Higuchi K, Watanabe T, Tominaga K, Kobayashi K. Ulcerogenicity and effect on inhibition of prostaglandin generation of indometacin farnesil, a prodrug of indomethacin, in rat gastric mucosa: comparison with indomethacin or loxoprofen. Drugs Exp Clin Res. 1995;21(3):85-8. PubMed PMID: 7555616.
11: Mishima M, Kobayashi S, Hashida R, Yuzuriha T, Sato T, Satoh T. Enzymatic hydrolysis of indometacin farnesil, a prodrug of indomethacin, by carboxylesterase in cultured synovial cells. Res Commun Chem Pathol Pharmacol. 1991 May;72(2):183-90. PubMed PMID: 1876749.
12: Kumakura S, Mishima M, Kobayashi S, Shirota H, Abe S, Yamada K, Tsurufuji S. Inhibitory effect of indomethacin farnesil, a novel antiinflammatory prodrug, on carrageenin-induced inflammation in rats. Agents Actions. 1990 Mar;29(3-4):286-91. PubMed PMID: 2339670.
13: Mishima M, Kobayashi S, Abe S, Yamato C. Metabolic fate of indometacin farnesil, a prodrug of indomethacin: characteristic biotransformation of indometacin farnesil in rats. Xenobiotica. 1990 Feb;20(2):135-46. PubMed PMID: 2333710.
14: Hara K, Akiyama Y, Kato Y, Orikasa E, Takahira H, Tajima T. [Influence of indometacin farnesil on blood coagulation. Comparison with indomethacin in normal rats and warfarin induced hypoprothrombinemic rats]. Nihon Yakurigaku Zasshi. 1988 Dec;92(6):365-73. Japanese. PubMed PMID: 3250914.
